![Page 1: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/1.jpg)
Angiotensin Receptors – NeprilysinInhibition (ARNI):
Mechanisms of Action, Effects and Side Effects
Uri Elkayam, MDProfessor of Medicine
University of Southern CaliforniaKeck School of Medicine
![Page 2: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/2.jpg)
The PARADIGM - HF Study
![Page 3: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/3.jpg)
Renin-Angiotensin-Aldosterone System
•1898 a Finnish physiologist and his Swedish medical students working in the Karolinska institute, discovered that saline extracts of rabbit renal cortex injected into rabbits, caused a pressor response. They named the active component of the extracts Renin.
![Page 4: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/4.jpg)
Braunwald E JACC 2015;65:1029-41
![Page 5: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/5.jpg)
Renin-Angiotensin-Aldosterone System
• 1940 two groups, one in Argentina and the second in the US demonstrated that renin catalyzed the formation of a peptide pressor substance that was called Angiotensin.
• They described 2 forms, the first an inactive decapeptide Angiotensin I that was cleaved by an enzyme (ACE) to the active octapeptide Angiotensin II.
![Page 6: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/6.jpg)
Effects of Angiotensin II
• Retention of Na+ and water by a direct proximal tubular effect and activation of aldosterone and vasopressin.
• Stimulates the thirst center of the brain.
• Stimulates cell proliferation, oxidative stress and fibrosis of the heart, kidneys and other organs.
• Stimulate the adrenal cortex to produce aldosterone.
• Stimulates cell proliferation, oxidative stress, and fibrosis.
![Page 7: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/7.jpg)
Stimulates cell proliferation,
oxidative stress, and fibrosis
![Page 8: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/8.jpg)
RAAS Inhibitors
•1977 the 1st ACE inhibitor, Captopril was developed and became a useful antihypertensive.
Gavras H et al NEJM 1978;298:991-5
![Page 9: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/9.jpg)
Circulation Research 1985
Stroke Volume Index
Ejection Fraction
End Diastolic Volume
![Page 10: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/10.jpg)
The SAVE Trial
![Page 11: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/11.jpg)
253 class IV HF patients randomized to placebo or enalapril 5-20 mg BID
![Page 12: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/12.jpg)
CONSENSUS TrialNot taking Vasodilators Taking
vasodilators
![Page 13: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/13.jpg)
The SOLVD StudyN Engl J Med 1991; 325:293-302
![Page 14: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/14.jpg)
SOLVD Treatment Trial
16%
2568 patients Class II-IIIEF≤ 35%
Progressive HF
Arrhythmias
HF Hospitalizations – 26%
22%
![Page 15: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/15.jpg)
SOLVD Prevention
N=4228Mortality – 8% P=0.30CV mortality – 12% P=0.12Death and HF hospitalizations -29% P<0.001
![Page 16: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/16.jpg)
SOLVD Prevention TrialN Engl J Med 1992; 327:685-691
![Page 17: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/17.jpg)
SOLVD Prevention N=4228
29%
20%
12%
![Page 18: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/18.jpg)
V-HeFT IIEffect of Enalapril vs. HYD/ISDN on all cause mortality
P = 0.016 at 2 years (28%) and 0.08 overall mortality difference due to decreased sudden death
Mortality reductionMore prominent in class I-II patients
N Engl J Med 1991; 325:303-310
![Page 19: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/19.jpg)
Sites of Action of ACEIs and ARBs
Renin
Angiotensinogen
Angiotensin I
ChymaseTrypsinPeptidase
Angiotensin II
ACE-Kininase II
ACEI Bradykinin è
Inactivedegradation
products
BK II-receptor
AT1 -receptor AT2 -receptor
AT1 -receptorblocker
X
X
X X
Vasoconstriction, CellGrowth (Remodeling)
Aldosterone secretion (Salt/water retention)
Cathecholamine release
Vasodilation, Inhibition of cell Growth, Natriuresis,Bradykinin release/NO/PGE
VasodilationNatriu-/diuresisAnti-remodeling
Willenheimer, R, et al., Europ Heart Journ 1999 (20):997-1008
NO
Major
importance
When level of
Renin and AII
Increased by
use
Of ACE-I AII can undergo
Further proteolysis
To AIII and AIV
which
Promote vaso-
constriction
B
CoughAngioedema
![Page 20: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/20.jpg)
Trials with ARBs in HF & Post-MITrial Population Drug Comparator Results
ELITE-2 CHF Class II-IV> 60 years
Losartan Captopril No benefit over captoprilLess cough
Val-HeFT CHF Class II-III Valsartan Placebo êHF M&Mparticularly in pts on no ACEi or BB. Worse in pts on both.
CHARMAlternativeAdded
CHF Class II-III Candesartan Placebo Reduced M&MAlter P- 0.0004Add-on P- 0.011
OPTIMAAL Post MI HF Losartan Captopril Both improve LV function,Trend favored Captopril
VALIANT Post MI HF Valsartan Captopril No benefit over Captopril alone or in combination
![Page 21: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/21.jpg)
2013 AHA/ACC GuidelinesACE Inhibitors
•ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortal-
(Class 1, Level of Evidence: A)
![Page 22: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/22.jpg)
2013 AHA/ACC GuidelinesACE Inhibitors
ARBs are recommended in patients with HFrEF with current or prior symptoms who are ACE inhibitor intolerant, unless contraindicated, to reduce morbidity and mortality. (Class 1, Level of Evidence: A)
![Page 23: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/23.jpg)
2013 AHA/ACC GuidelinesACE Inhibitors
ARBs are reasonable to reduce morbidity and mortality as alternatives to ACE inhibitors as first-line therapy for patients with HFrEF, especially for patients already taking ARBs for other indications, unless contraindicated. (Class IIa, Level of Evidence: A)
![Page 24: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/24.jpg)
Natriuretic Peptide System
In 1898 Tigerstedt and Bergman showed that infusion of extracts of rat atrium caused hypotension, > 30 fold increase of Na excretion and 10 fold increase in urine output and called it Atrial Natriuretic Factor.
![Page 25: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/25.jpg)
Natriuretic Peptide System
• In 1988 a peptide was identified in porcine brain that also caused hypotension, natriuresis and diuresis and was called Brain Natriuretic Peptide (BNP).
•BNP is also found in the heart and produced primarily from the ventricles.
![Page 26: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/26.jpg)
Natriuretic Peptides
![Page 27: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/27.jpg)
Physiologic Effects of Natriuretic Peptides
Neutral Endo-Peptidase
Corticotropin= hormone secreted by the adenohypophysis, having a stimulating effect on the adrenal cortex.
Decreased Cardiac and vascular remodeling,
apaptosis, myocardial hypertrophy and fibrosis
![Page 28: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/28.jpg)
BNP Concentration for the Degree of CHF Severity
BNP
Con
cent
ratio
n (p
g/m
l)
186 ± 22
791 ± 165
2013 ± 266
Mild(n=27)
Moderate(n=34)
Severe(n=36)
0
500
1000
1500
2000
2500
Maisel A. et al. J Am Coll Cardiol 2001;37(2):379-85
![Page 29: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/29.jpg)
The Natriuretic Peptide System is Overwhelmed in Acute Decompensated Heart Failure
Adapted from Burnett JC, J Hypertens 1999;17(Suppl 1):S37-S43
Angiotensin IIEpinephrine
EndothelinANP BNP
Aldosterone
A hallmark of HF isBNP resistance..
Just as Diabetes is anInsulin resistant disease
BNP in HF biologically inactive
![Page 30: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/30.jpg)
Pro BNP ProcessingMuch of BNP measured by contemporary assays is either nonprocessed (glycosylated) proBNP or degradation products of BNP 1-32 (BNP 3-32, 5-32, and 8-32).
Jaffe A. JACC 2015:65:666
![Page 31: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/31.jpg)
BNP and NTproBNPMcKie PM & Burnett JC JACC 2016 ;68:2437
![Page 32: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/32.jpg)
Natriuretic Peptides Testing in HFThe Influence of Neprilysin Inhibitors
![Page 33: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/33.jpg)
Hemodynamic Effects of NesiritideElkayam U et Al JACC Imaging 2008;1:765
![Page 34: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/34.jpg)
Hemodynamic Effects of NesiritideElkayam U et Al JACC Imaging 2008;1:765
![Page 35: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/35.jpg)
What is Neprilysin?•A plasma membrane glycoprotein, a metalloendopeptidase (neuropeptide- metabolizing enzyme), and the principle mechanism for degradation of the natriuretic peptides.
![Page 36: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/36.jpg)
Interaction of Individual NPs With NeprilysinPankow et al J Mol Biol 2009;393:469
![Page 37: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/37.jpg)
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With HF
Zile MR et al JACC 2016;68:2425–36
![Page 38: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/38.jpg)
What is Neprilysin?• Neprilysin also breaks down numerous other peptides including the vasodilators bradykinine, adrenomedullin, andbut also angiotensin I, angiotensin II, endothelin-1 and amyloid - β.
![Page 39: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/39.jpg)
![Page 40: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/40.jpg)
Adrenomodulline•A 52 amino acids peptide produced by the endothelium.
•Reduces myocyte hypertrophy, fibroblast proliferation, collagen synthesis and aldosterone secretion.
![Page 41: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/41.jpg)
Adrenomodulline•A strong peripheral and renal vasodilator, reduces vascular resistance and PCW pressure, increases CO, GFR, urine volume and Na excretion.
•Works by increasing cyclic AMP and activating NO.
![Page 42: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/42.jpg)
Hemodynamic Effect Of Adrenomedullin in HFNagaya N et al Circulation 2000;101:498
![Page 43: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/43.jpg)
Hemodynamic Effect Of Adrenomedullin in HFNagaya N et al Circulation 2000;101:498
![Page 44: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/44.jpg)
Renal Effects of Adrenomedullin in HFNagaya N et al Circulation 2000;101:498
Urin Volume
Urinary Na Excretion
Urinary K excretion
Creatinine Clearance
![Page 45: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/45.jpg)
Bradykinin•Bradykinin is a powerful vasodilator.
• Its vasodilatory effects result partially from NO release.
• Improves endothelial function.
•ACE inhibition enhances endothelium-mediated dilation in humans by a bradykinin-dependent mechanism.
![Page 46: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/46.jpg)
Role of Bradykinin in Mediating Vascular Effects of Angiotensin-Converting Enzyme Inhibitors in Humans
Hornig & Drexler Circulation 1997
Radial Artery Diameter During Reactive Hyperemia
![Page 47: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/47.jpg)
Comparison of Omapatrilat and Enalapril in HFThe OVERTURE Study
![Page 48: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/48.jpg)
Comparison of Omapatrilat and Enalapril in HFThe OVERTURE Study
The omapatrilat group had a 9% lower risk of CV death or hospitalization (P=0.024)
![Page 49: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/49.jpg)
Omapatrilat and Enalapril in Hypertension
Omapatrilat was superior to Enalapril in reducing BP. However, incidence of angioedema 3 times higher (0.7%
v 2.2%). Incidence higher in AA (1.6% v 5.5%).FDA declined to approve based on safety
![Page 50: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/50.jpg)
APP-Aminopeptidase
Aminopeptidase P
![Page 51: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/51.jpg)
Sites of Action of ACEIs and ARBs
Renin
Angiotensinogen
Angiotensin I
ChymaseTrypsinPeptidase
Angiotensin II
ACE-Kininase II
ACEI Bradykinin è
Inactivedegradation
products
BK II-receptor
AT1 -receptor AT2 -receptor
AT1 -receptorblocker
X
X
X X
Vasoconstriction, CellGrowth (Remodeling)
Aldosterone secretion (Salt/water retention)
Cathecholamine release
Vasodilation, Inhibition of cell Growth, Natriuresis,Bradykinin release/NO/PGE
VasodilationNatriu-/diuresisAnti-remodeling
Willenheimer, R, et al., Europ Heart Journ 1999 (20):997-1008
NO
Major
importance
When level of
Renin and AII
Increased by
use
Of ACE-I AII can undergo
Further proteolysis
To AIII and AIV
which
Promote vaso-
constriction
B
CoughAngioedema
![Page 52: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/52.jpg)
Interaction of Individual NPs With NeprilysinPankow et al J Mol Biol 2009;393:469
![Page 53: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/53.jpg)
![Page 54: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/54.jpg)
![Page 55: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/55.jpg)
Neprilysine in Heart FailureBayes-Genis JACC HF 2015;3:637
![Page 56: New Therapeutic Options for the Treatment of …laheartfailure.com/presentations/Elkayam_1.pdf · New Therapeutic Options for the Treatment of Hyperkalemia ... Global Mortality and](https://reader031.vdocument.in/reader031/viewer/2022030508/5ab7ec987f8b9ad13d8bef3a/html5/thumbnails/56.jpg)
Angiotensin Receptors – NeprilysinInhibition (ARNI):
Mechanisms of Action, Effects and Side Effects
Uri Elkayam, MDProfessor of Medicine
University of Southern CaliforniaKeck School of Medicine